Expressions of SPNS2 and Lgr5 in laryngeal squamous cell carcinoma and their correlations with prognosis / 国际肿瘤学杂志

ABSTRACT

Objective:To investigate the expressions of sphingosine-1-phosphate transporter 2 (SPNS2) and leucine-rich repeat-containing G-protein coupled receptor 5 (Lgr5) in laryngeal squamous cell carcinoma and their correlations with clinicopathological features and prognosis.Methods:A total of 82 cases of squamous cell carcinoma were collected from the paraffin-embedded specimens of laryngeal cancer in Taixing People′s Hospital of Jiangsu Province from March 2012 to March 2016. The expressions of SPNS2 and Lgr5 were detected by immunohistochemistry in 82 cancerous tissues and 50 adjacent normal tissues. The relationships between the expressions of SPNS2 and Lgr5 in patients with laryngeal squamous cell carcinoma and clinicopathological features and prognosis were analyzed.Results:The high expression rate of SPNS2 in laryngeal squamous cell carcinoma tissues was 40.24% (33/82), which was higher than 8.00% (4/50) in normal tissues adjacent to cancer. The high expression rate of Lgr5 in cancerous tissues was 46.34% (38/82), which was higher than 12.00% (6/50) in normal tissues adjacent to cancer. The differences were statistically significant ( χ2=16.008, P<0.001; χ2=16.484, P<0.001). The expression status of SPNS2 was related to tumor size ( χ2=5.713, P=0.017), tumor stage ( χ2=7.071, P=0.008), tumor differentiation degree ( χ2=5.722, P=0.017) and lymph node metastasis ( χ2=6.595, P=0.010). There were significant differences in the expression status of Lgr5 in different tumor stage ( χ2=8.200, P=0.004), tumor differentiation ( χ2=9.435, P=0.002) and lymph node metastasis ( χ2=16.188, P<0.001). The 3-year overall survival rate of patients in SPNS2 low expression group was 90.91%, which was higher than that of patients in SPNS2 high expression group (71.43%, χ2=4.975, P=0.026). The 3-year progression-free survival rate of patients in SPNS2 low expression group was 78.79%, which was higher than that of patients in SPNS2 high expression group (55.10%, χ2=6.113, P=0.013). The 3-year overall survival rate of patients in Lgr5 low expression group was 86.84%, which was higher than that of patients in Lgr5 high expression group (65.91%, χ2=5.801, P=0.016). The 3-year progression-free survival rate of patients in Lgr5 low expression group was 78.95%, which was higher than that of patients in Lgr5 high expression group (56.82%, χ2=6.316, P=0.012). Multivariate Cox regression analysis showed that differentiation ( RR=0.199, 95% CI 0.057-0.691, P=0.011), tumor staging ( RR=0.167, 95% CI 0.053-0.531, P=0.002), SPNS2 ( RR=0.208, 95% CI 0.072-0.604, P=0.004) and Lgr5 ( RR=0.198, 95% CI 0.060-0.655, P=0.008) were risk factors for the prognosis of patients with laryngeal squamous cell carcinoma. Contingency correlation analysis showed a positive correlation between SPNS2 and Lgr5 expressions in laryngeal squamous cell carcinoma ( C=0.591, P<0.001). Conclusion:SPNS2 and Lgr5 are highly expressed in laryngeal squamous cell carcinoma and are closely related to clinicopathological features. And SPNS2 and Lgr5 are risk factors for the prognosis of patients with laryngeal squamous cell carcinoma.